All In Biotech

Drug Trial Radar · NCT06346067

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

A Randomized, Open-label Phase III Study in Patients With Previously Treated Unresectable or Metastatic NRAS Mutant Cutaneous Melanoma Comparing the Combination of Naporafenib + Trametinib to Physician's Choice of Therapy (Dacarbazine, Temozolomide or Trametinib Monotherapy) With a Dose Optimization lead-in [SEACRAFT-2]

Last checked: Nov 20, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

78

Actual

Start

Apr 29, 2024

Primary completion

Apr 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Erasca, Inc.Industry
Sponsor type
Industry
First posted
Apr 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy).

Conditions

  • Advanced or Metastatic NRAS-mutant Melanoma

Interventions

  • NaporafenibDrug

    Naporafenib (ERAS-254) is an experimental Pan-Raf inhibitor

  • DacarbazineDrug

    Dacarbazine IV - Day 1

  • TemozolomideDrug

    Temozolomide 200 mg/m2/day PO on Day 1 to Day 5 of each 28-day cycle

  • TrametinibDrug

    Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2Time frame: Assessed up to 6 months from time of first dose
  2. Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2Time frame: Assessed up to 6 months from time of first dose
  3. Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2Time frame: Study Day 1 up to Day 29
  4. Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2Time frame: Study Day 1 up to Day 29
  5. Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2Time frame: Study Day 1 up to Day 29
  6. Stage 2: To compare PFS and OS for patients who are randomized to receive the combination of naporafenib + trametinib to that of patients who receive physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy)Time frame: Assessed up to 24 months from time of first dose

Locations

59 sites in 9 countries. Site status is shown where the registry gives one.

  • Mayo Clinic - Arizona

    Phoenix, Arizona

  • University of California, San Francisco

    San Francisco, California

  • The Melanoma and Skin Care Institute

    Englewood, Colorado

  • Mayo Clinic - Florida

    Jacksonville, Florida

  • University of Miami Sylvester Cancer

    Miami, Florida

  • University of Kansas Cancer Center

    Kansas City, Kansas

  • Ochsner Clinic Foundation

    Jefferson, Louisiana

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • SCRI Oncology Partners (formerly Tennessee Oncology)

    Nashville, Tennessee

  • Texas Oncology- Austin Midtown

    Austin, Texas

  • Texas Oncology - Baylor Charles A. Sammons Cancer Center

    Dallas, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • The University of Utah - Huntsman Cancer Institute (HCI)

    Salt Lake City, Utah

  • Virginia Oncology Associates

    Norfolk, Virginia

  • Fred Hutchinson Cancer Center

    Seattle, Washington

  • University of Wisconsin

    Madison, Wisconsin

  • Alfred Hospital

    Melbourne, Australia

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia

  • Tasman Health Care

    Southport, Queensland, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Peter MacCallum Cancer Institute

    Melbourne, Victoria, Australia

  • Hollywood Private Hospital

    Nedlands, Western Australia, Australia

  • Queen Elizabeth II Health Sciences Centre

    Halifax, Nova Scotia, Canada

  • McGill University Health Centre

    Montreal, Quebec, Canada

  • Masarykuv Onkologicky Ustav-MOU

    Brno, Czechia

  • Fakultni nemocnice Hradec Kralove

    Nový Hradec Králové, Czechia

  • Sanatorium Profesora Arenbergera

    Prague, Czechia

  • Centre Hospitalier Universitaire (CHU) de Bordeaux - Hospitalier Saint-Andre

    Bordeaux, France

  • CHU Dijon Bourgogne - Hopital Francois Mitterand (Hopital du Bocage)

    Dijon, France

  • Centre Hospitalier du Mans

    Le Mans, France

  • CHRU de Lille - Hôpital Claude Huriez

    Lille, France

  • Centre Hospitalier Lyon-Sud

    Lyon, France

  • Assistance Publique Hopitaux de Marseille (AP-HM) - Hopital de la Timone

    Marseille, France

  • Hospital Ambroise Pairs

    Paris, France

  • APHP - Hopital Saint Louis

    Paris, France

Showing 40 of 59 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.